LENZ
NASDAQ · Pharmaceuticals
Lenz Therapeutics Inc
$3.01
-0.45 (-13.01%)
Financial Highlights (FY 2026)
Revenue
24.20M
Net Income
-104,137,310
Gross Margin
97.8%
Profit Margin
-430.3%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 97.8% | 63.2% | 63.2% | 63.2% |
| Operating Margin | -477.5% | 33.9% | 41.1% | 35.1% |
| Profit Margin | -430.3% | 31.5% | 26.3% | 33.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 24.20M | 61.59M | 55.54M | 66.64M |
| Gross Profit | 23.67M | 38.94M | 35.11M | 42.13M |
| Operating Income | -115,568,281 | 20.87M | 22.83M | 23.42M |
| Net Income | -104,137,310 | 19.38M | 14.59M | 22.25M |
| Gross Margin | 97.8% | 63.2% | 63.2% | 63.2% |
| Operating Margin | -477.5% | 33.9% | 41.1% | 35.1% |
| Profit Margin | -430.3% | 31.5% | 26.3% | 33.4% |
| Rev Growth | — | +17.7% | +18.8% | -7.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 192.21M | 201.78M | 216.87M |
| Total Equity | — | 194.79M | 170.45M | 172.69M |
| D/E Ratio | — | 0.99 | 1.18 | 1.26 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -115,200,278 | 32.48M | 26.94M | 31.76M |
| Free Cash Flow | — | 24.80M | 19.95M | 25.11M |